Eli Lilly is investing $6.5 billion to build a major pharmaceutical manufacturing campus in Houston, expected to produce pill-form GLP-1 weight-loss drugs and other small-molecule medicines. The 236-acre facility will create approximately 600 permanent jobs and 4,000 construction positions, while the company is also funding $15 million in workforce development at San Jacinto College. Construction begins now with completion targeted for November 2027.
Eli Lilly CEO Dave Ricks told CNBC that one-third of new GLP-1 pill patients are taking Foundayo as the company ramps up production to compete with rival Novo Nordisk. Lilly broke ground on a $6.5 billion manufacturing facility in Houston expected to be operational by 2030, part of over $50 billion in manufacturing investments since 2020. Foundayo, which launched in April, generated $98 million in sales in its first quarter on the market.
A mathematical puzzle asks whether two arbitrarily shaped potatoes can each have a closed curve drawn on them that are identical as curves in 3D space. The post discusses how to formalize this puzzle mathematically, interpreting potatoes as compact surfaces and curves as embedded loops.
A 3-year-old with metastatic hepatoblastoma experienced complete cancer regression after receiving experimental GPC3-CAR T cell therapy, an immunotherapy that genetically engineers a patient's immune cells to target liver cancer. The boy, whose cancer had spread to his lungs and bones and recurred despite chemotherapy and surgery, remained disease-free 12 months after two infusions of the treatment. This case marks a significant advance in using CAR T cell therapy against solid tumors, though further trials are needed to confirm efficacy and safety.